Riociguat for pulmonary hypertension (Q37709398)

22 August 2017

1 reference

title

Riociguat for pulmonary hypertension. (English)

1 reference

22 August 2017

main subject

arterial hypertension

0 references

1 reference

Norbert Weissmann

0 references

Ralph Schermuly

0 references

Friedrich Grimminger

0 references

Werner Seeger

0 references

Robert Voswinckel

1 reference

22 August 2017

Hossein-Ardeschir Ghofrani

1 reference

22 August 2017

Henning Gall

1 reference

22 August 2017

publication date

1 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

1 reference

22 August 2017

1 reference

22 August 2017

page(s)

155-166

1 reference

Updated clinical classification of pulmonary hypertension.

22 August 2017

cites work

1 reference

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In

21 January 2018

1 reference

Primary pulmonary hypertension. A national prospective study

21 January 2018

1 reference

Wide variation in clinicians' assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension

21 January 2018

1 reference

Pulmonary hypertension: clinical manifestations, classification and diagnosis

21 January 2018

1 reference

Diagnosis and assessment of pulmonary arterial hypertension.

21 January 2018

1 reference

Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review

21 January 2018

1 reference

Diagnosis and differential assessment of pulmonary arterial hypertension

21 January 2018

1 reference

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

21 January 2018

1 reference

Improving survival in pulmonary arterial hypertension.

21 January 2018

1 reference

Pulmonary arterial hypertension in France: results from a national registry

21 January 2018

1 reference

An epidemiological study of pulmonary arterial hypertension

21 January 2018

1 reference

Treatment of pulmonary arterial hypertension

21 January 2018

1 reference

Pulmonary endarterectomy: experience and lessons learned in 1,500 cases

21 January 2018

1 reference

Expert opinion on available options treating pulmonary arterial hypertension

21 January 2018

1 reference

Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension.

21 January 2018

1 reference

Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan

21 January 2018

1 reference

Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.

21 January 2018

1 reference

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial

21 January 2018

1 reference

Immediate and Long-term Hemodynamic and Clinical Effects of Sildenafil in Patients With Pulmonary Arterial Hypertension Receiving Vasodilator Therapy

21 January 2018

1 reference

Efficacy and optimal dose of sildenafil in primary pulmonary hypertension

21 January 2018

1 reference

Rebound pulmonary hypertension after inhalation of nitric oxide

21 January 2018

1 reference

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential

21 January 2018

1 reference

Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations

21 January 2018

1 reference

Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide

21 January 2018

1 reference

Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.

21 January 2018

1 reference

Modulating cGMP to treat lung diseases.

21 January 2018

1 reference

Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers

21 January 2018

1 reference

Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension

21 January 2018

1 reference

First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension

21 January 2018

1 reference

Pulmonary Arterial Hypertension

21 January 2018

1 reference

Chronic Thromboembolic Pulmonary Hypertension

21 January 2018

1 reference

Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FCA.10.5

1 reference

release_wyieomnjwzajngqxmmikejeity

22 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wyieomnjwzajngqxmmikejeity

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference